These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 27848150)

  • 1. Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions.
    Fujita K; Kaneko M; Narukawa M
    Clin Drug Investig; 2017 Mar; 37(3):219-232. PubMed ID: 27848150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis.
    Kim YG; Hahn S; Oh TJ; Kwak SH; Park KS; Cho YM
    Diabetologia; 2013 Apr; 56(4):696-708. PubMed ID: 23344728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Co-Transporter 2 Inhibitors Between Japanese and Non-Japanese Patients: A Meta-Analysis.
    Ito Y; Ambe K; Hayase T; Kobayashi M; Tohkin M
    Clin Transl Sci; 2020 May; 13(3):498-508. PubMed ID: 31880866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethnic Difference in the Pharmacodynamics-efficacy Relationship of Dipeptidyl Peptidase-4 Inhibitors Between Japanese and non-Japanese Patients: A Systematic Review.
    Ito Y; Ambe K; Kobayashi M; Tohkin M
    Clin Pharmacol Ther; 2017 Oct; 102(4):701-708. PubMed ID: 28378919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
    Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies.
    Kozlovski P; Fonseca M; Mohan V; Lukashevich V; Odawara M; Paldánius PM; Kothny W
    Diabetes Obes Metab; 2017 Mar; 19(3):429-435. PubMed ID: 27943546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: A systematic review and meta-analysis.
    Kim YG; Min SH; Hahn S; Oh TJ; Park KS; Cho YM
    Diabetes Res Clin Pract; 2016 Jun; 116():86-95. PubMed ID: 27321321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
    Wu D; Li L; Liu C
    Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?
    Foley JE; Bhosekar V; Kawamori R
    Vasc Health Risk Manag; 2016; 12():9-12. PubMed ID: 26855580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
    Stoimenis D; Karagiannis T; Katsoula A; Athanasiadou E; Kazakos K; Bekiari E; Matthews DR; Tsapas A
    Expert Opin Pharmacother; 2017 Jun; 18(9):843-851. PubMed ID: 28448177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials.
    Esposito K; Chiodini P; Maiorino MI; Bellastella G; Capuano A; Giugliano D
    BMJ Open; 2014 Jun; 4(6):e005442. PubMed ID: 24916090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors : meta-regression analysis of 78 randomized controlled trials with 20,053 patients.
    Esposito K; Chiodini P; Capuano A; Maiorino MI; Bellastella G; Giugliano D
    Endocrine; 2014 May; 46(1):43-51. PubMed ID: 24248503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
    Horie Y; Kanada S; Watada H; Sarashina A; Taniguchi A; Hayashi N; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2011 Jul; 33(7):973-89. PubMed ID: 21723606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
    Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
    BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
    Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors.
    Hong S; Jung CH; Han S; Park CY
    Diabetes Metab J; 2022 Jan; 46(1):63-70. PubMed ID: 33866774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials.
    Zhang Y; Hong J; Chi J; Gu W; Ning G; Wang W
    Diabetes Metab Res Rev; 2014 Mar; 30(3):241-56. PubMed ID: 24123720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Placebo Effect between Asian and Caucasian Type 2 Diabetic Patients: A Meta-Analysis.
    Guo W; Nie L; Wang XR; Xu ML; Yang WJ; Gao XY; Cai XL; Ji LN
    Chin Med J (Engl); 2018 Jul; 131(13):1605-1612. PubMed ID: 29941715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of a sodium-glucose co-transporter-2 inhibitor versus placebo as an add-on therapy for people with type 2 diabetes inadequately treated with metformin and a dipeptidyl peptidase-4 inhibitor: a systematic review and meta-analysis of randomised controlled trials.
    De Buitléir C; O' Connor E; Satti MM; Shaw J; Liew A
    Diabet Med; 2021 Feb; 38(2):e14409. PubMed ID: 32979231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of subjects with type 2 diabetes enrolled in randomized controlled trials and non-randomized controlled trials in Japan: A systematic review.
    Kadowaki T; Shoji A; Taguchi Y
    J Diabetes Investig; 2023 Feb; 14(2):236-246. PubMed ID: 35726690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.